Every material Form 8-K Ultragenyx Pharmaceutical Inc. has filed with the SEC since October 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Ultragenyx reported third-quarter 2026 revenue of $173 million, up from $160 million a year earlier, and a net loss of $118 million, down from $180 million. The company also announced a restructuring that cuts about 20% of its workforce, ends the UX701 Wilson disease program, and expects about $25 million in charges in the fourth quarter. It reaffirmed its 2026 revenue guidance and its expectation of full-year GAAP profitability in 2027, and it completed the $210 million sale of a priority review voucher.
Q3 2026 total revenue was $173 million; net loss was $118 million, or $1.16 per share, versus $1.81 per share a year earlier
Restructuring expected to cost about $25 million, mostly severance, with substantially all charges in Q4 2026 and the workforce reduction substantially complete by end of 2026
Completed sale of the GENGLYCOS priority review voucher on October 30, 2026 for $210 million gross; 20% of proceeds payable to the NIH
Reaffirmed full-year 2026 total revenue guidance of $730 million to $760 million
Ultragenyx and Baylor Research Institute settled patent litigation with Navinta LLC over patents covering DOJOLVI oral liquid. Navinta will receive a non-exclusive, royalty-free license to market a generic version starting January 1, 2033, which would extend to July 1, 2033 if pediatric exclusivity is granted. The filing does not give a financial impact, and other ANDA patent litigation on DOJOLVI remains pending.
Settlement with Navinta LLC resolves patent litigation filed in the U.S. District Court for the District of New Jersey
Navinta's generic DOJOLVI license begins January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted
Similar patent litigation against other ANDA filers remains pending in the same court
Settlement agreement will be submitted to the FTC and the U.S. Department of Justice
Ultragenyx entered into an agreement on October 8, 2026, to sell a Rare Pediatric Disease Priority Review Voucher that the FDA awarded to the company on September 17, 2026, after approval of FAYUVI (UX111). The buyer agreed to pay $203 million in cash at closing, which remains subject to customary conditions, including the Hart-Scott-Rodino waiting period. For shareholders, the filing describes a $203 million cash payment that is not yet completed.
Agreement dated October 8, 2026; buyer to pay $203 million in cash upon closing
Voucher awarded by the FDA on September 17, 2026, upon approval of FAYUVI (UX111) for MPS IIIA (Sanfilippo syndrome Type A)
Closing subject to expiration or termination of the Hart-Scott-Rodino waiting period
Full agreement to be filed with the Form 10-K for the year ended December 31, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Ultragenyx Pharmaceutical Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →